The General Hospital Corporation Research Management Division, doing business as Massachusetts General Hospital (MGH), was awarded a $234,218 research grant from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394). The two-year project, titled "Response Assessment of Glioblastoma Using Magnetic Resonance Elastography," aims to validate the use of magnetic resonance elastography (MRE) to accurately differentiate between early tumor progression and pseudoprogression in glioblastoma patients following chemoradiotherapy. The research will leverage MGH's specialized expertise and facilities to map the spatial distribution of active tumor and treatment-related changes within the heterogeneous glioblastoma response, which is crucial for guiding subsequent treatment planning and improving patient outcomes.
Generated 2/25/25, 3:13 AM